XML 56 R47.htm IDEA: XBRL DOCUMENT
v3.23.3

Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($) $ in Thousands |  | 9 Months Ended |
--- | --- | --- | ---
Jun. 21, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022
Agreements |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs |  | $ 14,650 | $ 8,000 |
Contingent consideration under RPAs, AAAs and CPPAs |  | 4,000 |  | $ 75
Long-term royalty and commercial payment receivables |  | 74,696 |  | $ 63,683
Assignment and Assumption Agreement and Royalty Purchase Agreement |  |  |  |
Agreements |  |  |  |
Long-term royalty and commercial payment receivables | $ 6,000 |  |  |
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement |  |  |  |
Agreements |  |  |  |
Payments of consideration under RPAs, AAAs and CPPAs | 5,000 |  |  |
Maximum payments related to regulatory and commercial sales milestones | 6,000 |  |  |
Maximum payable on regulatory milestone | 5,000 |  |  |
Maximum payable in sales-based milestones | 1,000 |  |  |
Amount of allowance for credit losses |  | $ 0 |  |
LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones |  |  |  |
Agreements |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | 1,000 |  |  |
LadRx | Assignment and Assumption Agreement | Arimoclomol |  |  |  |
Agreements |  |  |  |
Maximum potential regulatory and commercial milestones, net | 52,500 |  |  |
Maximum payment obligations based on a portion of regulatory and commercial milestone payments | 9,500 |  |  |
LadRx | Royalty Purchase Agreement |  |  |  |
Agreements |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | 1,000 |  |  |
LadRx | Royalty Purchase Agreement | Regulatory milestones |  |  |  |
Agreements |  |  |  |
Contingent consideration under RPAs, AAAs and CPPAs | 1,000 |  |  |
LadRx | Royalty Purchase Agreement | Aldoxorubicin |  |  |  |
Agreements |  |  |  |
Maximum potential regulatory and commercial milestones, net | $ 342,700 |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details
Name: | us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements + References No definition available. + Details
Name: | xoma_ContingentConsiderationUnderPurchaseAgreements
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Long-term royalty and commercial rights receivables, non current. + References No definition available. + Details
Name: | xoma_LongTermRightsReceivableNonCurrent
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount payable on regulatory milestone. + References No definition available. + Details
Name: | xoma_MaximumPayableOnRegulatoryMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum amount payable on sales milestone. + References No definition available. + Details
Name: | xoma_MaximumPayableOnSalesMilestone
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum payment obligations based on a portion of regulatory and commercial milestone payments. + References No definition available. + Details
Name: | xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum potential regulatory and commercial milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments, under the agreement. + References No definition available. + Details
Name: | xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Maximum payments to be made based upon achievement of sales and/or regulatory milestones. + References No definition available. + Details
Name: | xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. + References No definition available. + Details
Name: | xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xoma_LadrxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_ArimoclomolMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xoma_AldoxorubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |